MediSieve

Executive Summary

MediSieve is a UK-based medical technology company pioneering a magnetic blood filtration platform that uses nanoengineered magnetic particles to selectively remove pathogens, harmful cells, toxins, and inflammatory cytokines directly from a patient's bloodstream. Founded in 2014 and based in London, the company aims to address a wide range of conditions with high unmet need, including sepsis, malaria, and autoimmune diseases. By offering a non-pharmacological, extracorporeal approach, MediSieve's technology could revolutionize treatment paradigms for acute and chronic diseases where existing therapies are limited or ineffective. The company is currently in a pre-revenue stage, with its platform undergoing preclinical and early clinical validation. MediSieve's technology has the potential to provide rapid, targeted blood purification without the side effects of systemic drugs. While specific funding and valuation details are not disclosed, the company's innovative approach positions it as a compelling candidate for further investment and partnership. Key upcoming milestones include initial clinical data readouts, securing Series A financing, and pursuing regulatory designations that could accelerate market entry.

Upcoming Catalysts (preview)

• Q3 2026Publication of pilot clinical study results for sepsis or malaria60% success
• Q2 2026Series A funding round closure70% success
• Q4 2026FDA Breakthrough Device Designation for lead indication50% success